• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nanotechnology >Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells
【24h】

Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells

机译：多功能化的氧化铁纳米颗粒，用于选择性地将药物递送至CD44阳性癌细胞

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nanomedicine nowadays offers novel solutions in cancer therapy and diagnosis by introducing multimodal treatments and imaging tools in one single formulation. Nanoparticles acting as nanocarriers change the solubility, biodistribution and efficiency of therapeutic molecules, reducing their side effects. In order to successfully. apply these novel therapeutic approaches, efforts are focused on the biological functionalization of the nanoparticles to improve the selectivity towards cancer cells. In this work, we present the synthesis and characterization of novel multifunctionalized iron oxide magnetic nanoparticles (MNPs) with antiCD44 antibody and gemcitabine derivatives, and their application for the selective treatment of CD44-positive cancer cells. The lymphocyte homing receptor CD44 is overexpressed in a large variety of cancer cells, but also in cancer stem cells (CSCs) and circulating tumor cells (CTCs). Therefore, targeting CD44-overexpressing cells is a challenging and promising anticancer strategy. Firstly, we demonstrate the targeting of antiCD44 functionalized MNPs to different CD44-positive cancer cell lines using a CD44-negative non-tumorigenic cell line as a control, and verify the specificity by ultrastructural characterization and downregulation of CD44 expression. Finally, we show the selective drug delivery potential of the MNPs by the killing of CD44-positive cancer cells using a CD44-negative non-tumorigenic cell line as a control. In conclusion, the proposed multifunctionalized MNPs represent an excellent biocompatible nanoplatform for selective CD44-positive cancer therapy in vitro.
机译：如今，通过在单一配方中引入多模式治疗和成像工具，纳米医学为癌症治疗和诊断提供了新颖的解决方案。充当纳米载体的纳米粒子改变了治疗性分子的溶解度，生物分布和效率，从而减少了它们的副作用。为了成功。应用这些新颖的治疗方法，努力集中在纳米粒子的生物学功能上，以提高对癌细胞的选择性。在这项工作中，我们介绍了具有抗CD44抗体和吉西他滨衍生物的新型多功能氧化铁磁性纳米颗粒（MNP）的合成和表征，及其在选择性治疗CD44阳性癌细胞中的应用。淋巴细胞归巢受体CD44在多种癌细胞中过表达，但在癌症干细胞（CSC）和循环肿瘤细胞（CTC）中也过表达。因此，靶向过表达CD44的细胞是一项具有挑战性和前途的抗癌策略。首先，我们证明了使用CD44阴性非致瘤细胞系作为对照，将抗CD44功能化的MNP靶向不同的CD44阳性癌细胞系，并通过超微结构表征和CD44表达下调来验证特异性。最后，我们通过使用CD44阴性非致瘤细胞系作为对照杀死CD44阳性癌细胞，显示了MNP的选择性药物递送潜力。总之，拟议的多功能MNPs代表了一种出色的生物相容性纳米平台，可用于体外选择性CD44阳性癌症治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号